

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 July 2020 (30.07.2020)



(10) International Publication Number
WO 2020/152306 A1

(51) International Patent Classification:

A61K 35/766 (2015.01) C12N 15/86 (2006.01)
C07K 14/005 (2006.01)

(21) International Application Number:

PCT/EP2020/051701

(22) International Filing Date:

24 January 2020 (24.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19153668,9 25 January 2019 (25.01.2019) EP

(71) Applicants: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **VIRATHERAPEUTICS GMBH** [AT/AT]; Bundesstraße 27, 6063 Rum (AT).

(72) Inventors: **MUELLER, Philipp**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **ERB, Klaus**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **ERLMANN, Patrik**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **NOLDEN, Tobias**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **PARK, John Edward**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **WOLLMANN, Guido**; c/o Medizinische Universitaet Innsbruck, Peter-Mayr-Strasse 4b, 6020 Innsbruck (AT).

(74) Agent: **SIMON, Elke Anna Maria** et al.; Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

WO 2020/152306 A1

(54) Title: RECOMBINANT RHABDOVIRUS ENCODING FOR CCL21

(57) Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.